Comparing the immune abnormalities in MIS-C to healthy children and those with inflammatory disease reveals distinct inflammatory cytokine production and a monofunctional T cell response

Butters, Claire; Benede, Ntombi; Moyo-Gwete, Thandeka; Richardson, Simone I.; Rohlwink, Ursula; Shey, Muki; Ayres, Frances; Manamela, Nelia P.; Makhado, Zanele; Balla, Sashkia R.; Madzivhandila, Mashudu; Ngomti, Amkele; Baguma, Richard; Facey-Thomas, Heidi; Spracklen, Timothy F.; Day, Jonathan; van der Ross, Hamza; Riou, Catherine; Burgers, Wendy A.; Scott, Christiaan; Zühlke, Liesl; Moore, Penny L.; Keeton, Roanne S.; Webb, Kate

doi:10.1016/j.clim.2023.109877

Cited by 2 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Klocperk et al described few differences between patients with PIMS-TS and healthy post-COVID-19 children, where children with this complication were characterized with elevated IFN-

activity, increased serum cytokine B cell activating factor (BAFF) and decreased proliferation-inducing ligand (APRIL) concentration [ 18 ]. In a similar study, Butters et al found that children with PIMS-TS had a lower proportion of polyfunctional SARS-CoV-2-specific CD4+ T cells compared to healthy SARS-CoV-2 seropositive children, while the level of monofunctional SARS-CoV-2-specific CD4+ T cells was high in both groups [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Programmed Cell Death Protein-1 Regulation in Response to SARS-CoV-2 in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2: A Prospective Cohort Study

Opoka-Winiarska,

Grywalska,

Morawska-Michalska

et al. 2024

IJMS

View full text Add to dashboard Cite

The role of programmed death cell protein 1 (PD-1) has already been described in a range of various diseases, including COVID-19. This study provides new, innovative data, related to the expression of PD-1 and the risk of Paediatric Inflammatory Multisystem Syndrome, temporally associated with SARS-CoV-2 infection (PIMS-TS)—a rare, but potentially life-threatening complication of COVID-19. In this study, we evaluated the expression of PD-1 protein in patients with PIMS. Blood samples were taken from patients at the time of diagnosis (n = 33), after 6 weeks (n = 33), 3 months (n = 24), 6 months (n = 24) and 12 months (n = 8). The immunophenotypes were evaluated in flow cytometry. The control group consisted of 35 healthy children with negative SARS-CoV-2 antigen/PCR test, who were asymptomatic and had no history of allergic, autoimmune or oncological diseases. The associations between immunophenotypes, biochemical findings and clinical data were analysed. Significant increases in the expression of PD-1 for CD4+ and CD8+ T cells, compared to the control group, were observed in the day of admission, with a gradual decrease during the first weeks from initiation of treatment. This study sheds new light on the pathogenesis of PIMS-TS, emphasizing the role of PD-1 protein. Future research is essential for early risk prediction in SARS-CoV-2 patients and for devising effective clinical prevention and management strategies.

show abstract

“…Klocperk et al described few differences between patients with PIMS-TS and healthy post-COVID-19 children, where children with this complication were characterized with elevated IFN-

Section: Discussionmentioning

confidence: 99%